Alkermes plc (ALKS) — Fair Value Analysis

Base-case fair value (P50): $57.63 · Current price: $49.06 · Verdict: Undervalued

The Verdict on ALKS

Monte Carlo simulations suggest ALKERMES (ALKS) is currently Fairly Valued. With the stock trading at $49.06, our robust median fair value (P50) stands at $57.63, indicating a potential +17.5% from current levels. This analysis incorporates thousands of forward-looking scenarios to establish a dynamic fair value range. While a positive +17.5% might suggest some near-term headroom, the close proximity of $49.06 to our $57.63 estimate strongly underpins the "Fairly Valued" assessment, aligning ALKS's current market price closely with its modeled intrinsic worth.

How ALKS stacks up against Healthcare

In the highly dynamic Healthcare sector, ALKS maintains an average quality tier, reflecting its operational and financial health when compared to its industry peers. This average standing is consistent with a valuation that indicates neither significant undervaluation nor pronounced overvaluation. The Monte Carlo analysis, factoring in these sector-specific dynamics, positions ALKS's $49.06 as reasonable when weighed against its $57.63 fair value, which still offers an +17.5%. This implies the market is pricing ALKS efficiently, recognizing its integrated strengths and limitations within the competitive Healthcare landscape.

What this means for investors

For investors tracking ALKS, the Monte Carlo simulation points to a stock that is largely Fairly Valued. While the $49.06 currently sits below the $57.63 median fair value, presenting a +17.5%, this indicated gap is not substantial enough to categorize ALKS as deeply undervalued based on our probabilistic models. Our simulations suggest the market has largely priced in the company's expected performance, growth trajectory and risk profile. Investors interested in understanding the full spectrum of possibilities, including both potential downside scenarios and more optimistic bull cases beyond the $57.63, can delve deeper into our detailed analysis. Sign up for FairCurve to see the full bear/bull distribution and track ALKS's fair value as new fundamentals are released.